Many datasets provide scale but limited clinical context. Traditional chart audits can provide depth but are often treated as one-off snapshots.
Tudor Data closes this gap.
Our programmes are designed around the patient. They combine a representative view of a disease population, with a longitudinal understanding of each patient’s journey to date, from diagnosis and monitoring through treatment and current management.
Where deeper visibility is needed, targeted sampling brings rare, niche or priority patient groups into clearer view.
Tudor Health captures longitudinal patient-level data directly from HCPs using a unique proprietary method that is designed for use in all disease areas, all specialities, and all countries..
Our data capture is NOT drawn directly from EMR software. This allows us to capture data from institutions with any EMR technology. We establish a strong relationship with individual HCPs to capture data, not a technology link.
Our longitudinal data are captured by updating data on the same set of patients. This gives us the opportunity to gradually expand the extent of the data held on each patient, which gives us greater depth of analytical options.
Identify the patient characteristics, treatment situations and care settings associated with treatment, non-treatment, switching or discontinuation.
Understand how clinical need, disease stage, treatment burden, suitability, access, tolerability and perceived benefit shape patient management.
See how patients move through diagnosis, monitoring, treatment initiation, persistence, switching and discontinuation.
Compare patient pathways, treatment behaviour and unmet needs across markets and priority patient groups.
We use complex sampling techniques to ensure that we have sufficient data on rare cohorts to give analytical reliability. By over-sampling rare cohorts we provide insights at a level that other sources find difficult.
The Tudor Health data model uses an identical data-capture method in all countries. This makes the data consistent within country and comparable across countries.
Tudor programmes are designed around the questions that Early Pipeline, Commercial Assessment, Marketing, Medical Affairs, Market Access and Insights teams need to answer.
Assess patient opportunity, unmet need, current treatment pathways and market readiness to inform early asset decisions.
Identify the patient groups, markets and treatment situations that matter most.
Explore early use, patient selection, source of business and whether real-world use reflects the intended positioning.
Understand diagnosis, monitoring, treatment initiation, persistence, switching, discontinuation and expected next steps.
Build or validate patient and HCP segments using detailed patient-level behaviour and decision context.
Measure patient, pathway and treatment indicators consistently across markets and understand how they change over time.
We explore a case study where patient-level EMR-equivalent data was collected from institutions that are…
In this brief paper we outline two areas of PLD where the Tudor Health methods…
There has been increased discussion in the USA in the past week regarding…